As changes in PI3K-Akt-mTor signaling are already known to be associated with AML and have recently been linked to chemoresistance, inhibition of PI3K-Akt-mTOR is already considered to be a potential therapeutic strategy in AML [35,36,37,38]. This evidence concerns the gene AKT1 and acute myeloid leukemia.